5-Year survival in Danish patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy.
Birgitte BjørnhartMette Thune MouritzenCharlotte KristiansenTine SchytteKim WedervangMette PøhlKarin Holmskov HansenPublished in: Acta oncologica (Stockholm, Sweden) (2023)
Compared to RCTs, long-term OS and PFS rates are lower in real-world patients treated with ICI in first line but much improved compared to historic rates on chemotherapy. A promising flattening of both the OS and progression free survival curves illustrates that also a subset of real-world patients obtain long-term remission. Patients with PS 2 and PD-L1 ≥ 50% may obtain clinically meaningful 2-year PFS and OS rates.
Keyphrases
- free survival
- advanced non small cell lung cancer
- end stage renal disease
- newly diagnosed
- epidermal growth factor receptor
- ejection fraction
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- squamous cell carcinoma
- clinical trial
- open label
- rheumatoid arthritis
- ulcerative colitis
- study protocol
- systemic lupus erythematosus
- rectal cancer